Skip to main content

Table 3. HCRA monetised consequences from 2014 to 2021 adjusted to 2021 values

From: The impact of a regionally based translational cancer research collaborative in Australia using the FAIT methodology

  1. a100% of the first eight items were attributed to the HCRA as it was determined that none of this funding would have been leveraged without the existence of HCRA
  2. bAll value in Australian Dollars, adjusted to 2021 value
  3. cOther categories of funding were not collected for this analysis
  4. Sensitivity analysis not required for these items
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us